Table 4 Sarcoma advisory group guidelines—ewing sarcomas
Category | 1st line | 2nd line | 3rd line and other |
|---|---|---|---|
Localised or metastatic disease with lung or pleural metastases only | VIDE 6 cycles VAC or VAI × 8 cycles [142] | High dose ifosfamide [144] or Ifosfamide and etoposide or cyclophosphamide and topotecan [145] or irinotecan and temozolamide [146] ± High dose chemotherapy (busulphan/lmelphalan or treosulphan/melphalan) with peripheral blood stem cell rescue [147] N.B. Choice of 2nd line therapy will depend on patient/disease specific factors (e.g. if chemo being given with curative intent) and/or patient choice | Cyclophosphamide and topotecan [145] or Irinotecan and temozolamide [146] or gemcitabine and docetaxel [148, 149] or oral etoposide [150] or cisplatin and etoposide |
Metastatic disease with bone or bone marrow involvement | VIDE × 6 cycles → VAC or VAI × 8 cycles [142, 143] or VDC/IE interval compressed regimen × 14 cycles [140] |